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ABSTRACT
Objective To review comparisons of the effectiveness of 
endovascular stent grafting (ESG) against open surgical 
repair (OSR) for treatment of chronic arch or descending 
thoracic aortic aneurysms (TAA).
Design Systematic review and meta- analysis
Data sources MEDLINE, EMBASE, CENTRAL, WHO 
International Clinical Trials Routine data collection, current 
controlled trials, clinical trials and the NIHR portfolio were 
searched from January 1994 to March 2020.
Eligibility criteria for selective studies All identified 
studies that compared ESG and OSR, including randomised 
controlled trials (RCTs), quasi- randomised and non- RCTs, 
comparative cohort studies and case–control studies 
matched on main outcomes were sought. Participants 
had to receive elective treatments for arch/descending 
(TAA). Studies were excluded where other thoracic aortic 
conditions (eg, rupture or dissection) were reported, unless 
results for patients receiving elective treatment for arch/
descending TAA reported separately.
Data extraction and synthesis Data were extracted by 
one reviewer and checked by another. Risk of Bias was 
assessed using the ROBINS- I tool. Meta- analysis was 
conducted using random effects. Where meta- analysis not 
appropriate, results were reported narratively.
Results Five comparative cohort studies met inclusion 
criteria, reporting 3955 ESG and 21 197 OSR patients. 
Meta- analysis of unadjusted short- term (30 day) all- cause 
mortality favoured ESG (OR 0.75; 95% CI 0.55 to 1.03)). 
Heterogeneity identified between larger and smaller 
studies. Sensitivity analysis of four studies including only 
descending TAA showed no statistical significance (OR 
0.73, 95% CI 0.45 to 1.18)), moderate heterogeneity. 
Meta- analysis of adjusted short- term all- cause mortality 
favoured ESG (OR 0.71, 95% CI 0.51 to 0.98)), no 
heterogeneity. Longer- term (beyond 30 days) survival from 
all- cause mortality favoured OSR in larger studies and 
ESG in smaller studies. Freedom from reintervention in the 
longer- term favoured OSR. Studies reporting short- term 
non- fatal complications suggest fewer events following 
ESG.
Conclusions There is limited and increasingly dated 
evidence on the comparison of ESG and OSR for treatment 
of arch/descending TAA.
PROSPERO registration number CRD42017054565.
INTRODUCTION
Rationale
A thoracic aortic aneurysm (TAA) is an 
abnormal expansion of the aorta at any part 
of its course from the heart to the diaphragm. 
Aneurysms manifest with acute symptoms 
or they may be chronic. If untreated, TAA 
can continue to expand and the annual risk 
of aneurysm rupture increases from 2% in 
aneurysms smaller than 5 cm in diameter 
to 7% in aneurysms over 6 cm in diameter.1 
The majority of aneurysms (and there-
fore studies) centre on the ascending or 
abdominal segments of the aorta, arch and 
descending aneurysms are relatively under-
studied. Therefore, this review focused on 
chronic aneurysms affecting the arch or 
descending thoracic aorta (DTA).
There are currently two main methods 
of repair for arch/descending TAA: 
open surgical repair (OSR) and endovas-
cular stent grafting (ESG). OSR involves 
replacing the aneurysmal segment of aorta 
with a surgical graft during open surgery 
using heart- lung bypass. As the arch and 
descending aorta supply blood to the 
Strengths and limitations of this study
 ► This is the first systematic review to investigate two- 
armed studies looking only at elective endovascular 
stent grafting versus open surgical repair for treat-
ment of chronic arch or descending thoracic aortic 
aneurysms. Other reviews include dissections, rup-
tures and treatment for other conditions.
 ► This systematic review inclusion criteria were broad 
and sought to include evidence from both ran-
domised and non- randomised study designs.
 ► Statistical analysis of non- fatal complications was 
not possible due to the limited and inconsistent re-
porting of such complications.
 on M









pen: first published as 10.1136/bm





2 McCarthy A, et al. BMJ Open 2021;11:e043323. doi:10.1136/bmjopen-2020-043323
Open access 
brain and spinal cord, OSR is high risk, with reported 
mortality and paraplegia rates of approximately 5% 
and 10%,2 respectively. In ESG, a stent is placed across 
the aneurysm, providing a new conduit through which 
the blood flows. ESG is most often selected for patients 
who are considered at high risk of death or permanent 
disability from OSR. However, some patients may not 
have a suitable anatomy/morphology for ESG proce-
dures.2 Concerns have also been raised about long- term 
durability and safety of the implanted devices3 4 due to 
complications such as stent migration or endoleaks, 
with the incidence of late endoleaks (leaks around or 
through the stent graft that occur more than 1 year 
after insertion) reported as being between 2.5% and 
27.8%.5 The need for reintervention due to technical 
failures of the stent following ESG is also high (23% 
at 5 years).6 7 With each reintervention there is an 
added risk of complication either due to the increased 
complexity of the procedure or deteriorating health of 
the patient.2
One previous systematic review comparing only elec-
tive OSR and ESG for descending and arch TAAs has 
been reported.8 This systematic review8 was restricted to 
data from randomised controlled trials (RCTs) in which 
patients were randomly assigned to ESG and OSR, but 
no eligible trials were identified when searching relevant 
data based up to January 2016. There are other system-
atic reviews9 10 that have included non- randomised 
studies; however, these reviews also included emergency 
cases and other thoracic aortic pathologies (eg, dissec-
tion or rupture). As such, they may not represent a true 
comparison of elective ESG and OSR procedures for 
DTA aneurysms. Given the lack of RCT evidence, this 
systematic review includes non- randomised compara-
tive studies of the relative effectiveness of OSR or ESG.
The decision to operate requires a favourable 
balance between the risks and benefits of that inter-
vention compared with those attached to the expected 
outcomes of the disease. This balance is in turn influ-
enced by a number of factors. Aneurysm size correlates 
to the risk of death (if left untreated) and so patients 
are usually referred once the aneurysm crosses a 
chosen threshold. At that point, patient fitness (and 
life expectancy), the reality or possibility of an intrinsic 
weakness affecting the whole aorta, the technical feasi-
bility of the proposed intervention and patient wishes, 
come into play. This systematic review takes a step back 
from these issues and examines only the outcomes for 
patients in whom a decision to intervene has been 
made. This review is an essential starting point for 
the analysis of effective treatments for thoracic aortic 
aneurysms.
Objectives
The aim of this systematic review was to assess the effec-
tiveness of ESG compared with OSR as a treatment for 
chronic arch or descending TAA.
METHODS
Protocol and registration
The review protocol was registered in the PROSPERO 
database (CRD42017054565).11
Patient and public involvement
There was no patient and public involvement in the whole 
process of conducting this review.
Eligibility criteria
Study designs
All identified studies that directly compared ESG and 
OSR, including RCTs, quasi- randomised and non- RCTs, 
comparative cohort studies and case–control studies 
matched on main outcomes were sought.12
Non- randomised studies that controlled for selection 
bias were included—irrespective of study size. Acceptable 
methods for addressing selection bias included matching 
patients at baseline for important covariates, matching 
patients using propensity scores or adjustment for 
important covariates during analysis. Non- randomised 
studies that did not use these methods but included 
larger sample sizes (more than 250 patients) were also 
included as they have the potential to reduce sampling 
variation relative to smaller unmatched studies.13
Non- English language papers were noted and, where 
possible, data were extracted from the abstract. No trans-
lation of full- text articles was possible.
Study participants
Study participants had to receive elective treatments for 
arch and/or DTA aneurysms. Where emergency inter-
ventions or other thoracic aortic conditions (such as 
intramural haematoma, rupture and dissection) were 
reported, studies were excluded, unless results for patients 
receiving elective treatment for arch/descending TAA 
were reported separately. Studies that reported secondary 
(reintervention) procedures for arch/descending TAAs 
were included only if the original, primary procedure for 
each participant could be identified.
Study interventions
OSR was defined as replacement of the aneurysmal aorta 
with a prosthetic conduit via a sternotomy or thoracotomy 
with circulatory support. ESG was defined as transluminal 
introduction of a stent- graft under X- ray guidance.
Outcome measures
This review assessed short- term and long- term clinical 
effectiveness. Short- term was defined as either within 
30 days of the intervention and/or time until discharge 
following the intervention. Since most studies did not 
report long- term outcomes conditional on surviving the 
short- term period, long- term analyses covered the time 
from intervention until the end of follow- up. Primary 
outcomes were all- cause mortality and aneurysm- related 
mortality. Secondary outcomes were reinterventions and 
non- fatal complications. The latter were subclassified as 
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vascular, neurological, cardiac, respiratory and ‘other’ 
complications.
Information sources
MEDLINE, EMBASE, CENTRAL, WHO International 
Clinical Trials Routine data collection, Current Controlled 
Trials, Clinical Trials, and the UK National Institute for 
Health Research portfolio were searched. The search 
strategy (online supplemental appendix 1) was adapted 
as appropriate for each database (for example to allow 
for variations in controlled vocabulary terms and syntax.14 
Electronic searches identified publications between 1994, 
date of first reported case of ESG for descending and arch 
TAA,15 and March 2020.
Websites of regulatory bodies and Health Technology 
Assessment agencies were screened for unpublished rele-
vant reports. A citation search of all included studies was 
conducted via Web of Science. Studies from systematic 
reviews that satisfied the inclusion criteria of this review 
were screened for eligibility.
Study selection
All titles and abstracts were screened by one reviewer 
(AM). A second investigator (JG) reviewed 10% of all 
titles and abstracts classed as eligible or not eligible and 
all titles and abstracts classified as unclear by the first 
reviewer. The full text of selected studies was assessed 
by one investigator (AM) and classified as relevant, not 
relevant or unclear according to the inclusion criteria. 
A second investigator (JG) reviewed 10% of all papers, 
as well as all studies deemed unclear. Disagreements at 
either stage were resolved by discussion and where neces-
sary a third reviewer (PM) arbitrated. Where required, a 
clinical expert (PS) was asked to screen papers.
Data collection process
A data extraction form was developed based on The 
Cochrane Collaboration data collection form.16 Data 
were extracted by one reviewer (AM) and checked by a 
second reviewer (JG) for accuracy. Disagreements were 
resolved by discussion or arbitration by a third reviewer 
(PM).
Data items
Reported short- term and longer- term all- cause mortality, 
as well as short- term and longer- term aneurysm- related 
mortality were collected. All reported complications were 
recorded and grouped according to expert clinical guid-
ance as described above as neurological, cardiac, respi-
ratory or ‘other’ complications, with endoleaks following 
ESG recorded separately.
Risk of bias in individual studies
Risk of bias tools used were specific to the study design. 
As described later only non- randomised study designs 
were identified. Therefore, the ROBINS- I tool17 ("Risk 
Of Bias In Non- randomised Studies - of Interventions") 
was used. The ROBINS- I tool classifies the risk of bias in 
seven domains (confounding; selection of participants; 
classification of interventions; deviations from intended 
interventions; missing data; measurement of outcomes; 
selection of the reported results) and overall as either 
critical, severe, moderate, low or unclear.
Synthesis of results
Point estimates and precision of the incidence of short- 
term and long- term events and unadjusted and adjusted 
comparisons (ORs and HRs) were recorded. Meta- 
analysis of short- term event comparisons was based on 
the OR with 95% CI and conducted using RevMan.18 An 
overall treatment effect was calculated for the log (OR) of 
each outcome using a (normal) Mantel- Haenszel (M- H) 
random- effects model. Where comparisons could not be 
made, data were tabulated and reported narratively.
Heterogeneity between studies was assessed according 
to Cochrane guidelines, on clinical criteria, by visual 
inspection of plots of the data, from the χ2 test for 
heterogeneity, and the I- squared statistic. An I2 statistic 
of 25%–50% indicated low heterogeneity; 50%–75% indi-




The search identified 5163 unique studies. Of these, 
5078 studies were not eligible. Ineligibility was primarily 
because of irrelevant anatomy (ascending, abdominal 
or peripheral aneurysms), irrelevant pathology (acute 
dissection or other acute aortic syndromes) or because 
the study pooled data from a mixture of anatomical and 
pathological situations such that data on chronic arch 
and DTA aneurysms could not be extracted with confi-
dence. Thus, 85 papers underwent full- text screening. 
Seventy- five papers were rejected at this stage leaving 
10 papers to be included in the full review. Six papers 
reported data from the Gore TAG Trial,19–24 leaving five 
unique comparative studies that fulfilled the inclusion 
criteria. Further details of the selection process are shown 
in the Preferred Reporting Items for Systematic Reviews 
and Meta- Analyses diagram (figure 1).
One study, Goodney et al25 reported both an unad-
justed analysis for the unadjusted cohort and an anal-
ysis of a subgroup of propensity score matched patients. 
Data from the unadjusted cohort were used in all meta- 
analyses except the adjusted mortality meta- analysis, 
which used the propensity matched data. Brief summaries 
of the identified studies are given in table 1, with detail 
provided in online supplemental appendix 2. Overall, the 
five studies included data on 3955 ESG and 21 197 OSR 
patients and all studies were conducted in Europe or the 
USA. Two studies had non- overlapping or only partially 
overlapping recruitment periods between the ESG and 
OSR intervention groups (Gore Tag19–24 and Piffaretti et 
al).26 There were clear differences in patient characteris-
tics between the two treatment groups. ESG patients were 
consistently older, with average age differences ranging 
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from 2 to 9 years in all but one analysis (Goodney et al25 
the propensity matched cohort). Similarly, in most studies 
the proportion of men was greater in the ESG group.
Risk of bias within studies
The propensity- matched analysis of Goodney et al25 was 
judged to be of overall moderate risk of bias and four 
studies were at severe risk of bias due to the potential for 
confounding (online supplemental appendix 3).
Two large cohorts derived from UK and USA admin-
istrative databases (von Allmen et al27 and Hughes et al28 
did not attempt to address selection bias at the design 
stage, but did adjust for some confounders in the anal-
ysis. A third study (Goodney et al,25 using USA adminis-
trative data, included both unadjusted population and 
analysis of a subset of the data defined by propensity score 
matching. Propensity score methods rely on all important 
confounders being available and included.29 As this study 
did not include all confounders considered important, 
such as aneurysm size, this study was judged to have 
moderate risk of bias due to confounding.
One study (Gore TAG)19–24 included only ESG patients 
who would also have been eligible for OSR and the another 
study (Piffaretti et al)26 included only OSR patients who 
would be suitable for ESG, both according to clinician 
judgement. Since suitability was decided retrospectively, 
such matching may not be robust.
A further potential bias with each study was selective 
reporting. Although the measurements and analyses of 
the outcomes were clearly defined within each study, no 
evidence of a prestudy analysis plan was identified.
Synthesis of results
Short-term death from any cause (30-day or in hospital)
Unadjusted mortality
All five studies19–28 reported unadjusted 30 days or in- hos-
pital mortality (figure 2). Overall, the odds of short- term 
mortality were lower in the ESG group than the OSR group 
(OR: 0.75; 95% CI 0.55 to 1.03). Moderate heterogeneity 
was present in the overall analysis (I2=40%), mainly due 
to differences between the two smaller studies19–24 26 and 
the three larger studies,25 27 28 with a large I2 for subgroup 
differences between the larger studies subgroup and the 
smaller studies subgroup of 84.5%.
For the three larger studies25 27 28 (3798 ESG and 21 092 
OSR patients), the treatment effect for death was smaller 
(OR 0.84 95% CI 0.72 to 0.98)) than that for the two 
smaller studies19–24 26 (157 ESG and 105 OSR patients, 
combined OR 0.18 95% CI 0.06 to 0.59)). There was 
no evidence of heterogeneity in results between these 
subgroups (I2=0).
Sensitivity analysis
Hughes et al28 was the only study to include aortic arch 
aneurysms. Arch aneurysms tend to be more complex 
procedures and are mostly conducted using OSR. A 
sensitivity analysis excluding this study was, therefore, 
conducted (figure 3).
While the point effect estimates all favoured ESG, 
the overall pooled OR (OR 0.73; 95% CI 0.45 to 1.18)) 
did not reach statistical significance (p=0.2). Moderate 
heterogeneity was present in the overall analysis (I2=42%), 
mainly due to differences between the two smaller studies 
and the two larger studies, with a large I2 for subgroup 
differences between the larger studies subgroup and the 
smaller studies subgroup of 65.1%.
For the two larger studies25 27 (3086 ESG and 12 837 OSR 
patients), the treatment effect for death was smaller (OR 
0.85; 95% CI 0.72 to 1.00)) than that for the two smaller 
studies19–24 26 (157 ESG and 105 OSR patients, combined 
OR 0.20; 95% CI 0.04 to 1.06)). There was no evidence of 
heterogeneity in results within the large subgroup (I2=0) 
and evidence of low heterogeneity withing the small 
studies subgroup (I2=26%).
Adjusted mortality
The three larger studies25 27 28 included adjusted analysis 
of short- term mortality (figure 4). Goodney et al25 used 
stratified propensity matching. Hughes et al28 adjusted 
Figure 1 PRISMA diagram. PRISMA, Preferred Reporting 
Items for Systematic Reviews and Meta- Analyses
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for preoperative comorbidities, independent predictors 
of mortality and postoperative complications and the von 
Allmen et al27 study adjusted for age and sex. The OR for 
ESG, relative to OSR, for these three studies combined 
was 0.71, 95% CI 0.51 to 0.98). No evidence of heteroge-
neity was identified in this meta- analysis (I2=0%)
Table 1 Study characteristics
Study
von Allmen et al 
201427
Goodney et al 201125
(Two analyses*) Gore TAG Hughes et al 201428
Piffaretti et al 
200726
Mthods           
Study design Comparative 
cohort






ESG patients judged 
eligible for OSR
None OSR patients 
judged eligible for 
ESG
Participants           






Multicentre Multicentre Single centre
Time frame 2006–2011 1. 1998–2007
2. 2003–2007
ESG 1999- 2001, 








1. Total 13 998 (ESG 
2433, OSR 11,565)











Age summary Median (IQR)
ESG 73 (66,78), 
OSR 71 (63–76)
Mean (95% CI)
1. ESG 75.9 (75.6 to 
76.1), OSR 73.8 (73.7 
to 73.9)
2. ESG 71.1 (70.8 to 
71.4), OSR 70.7 (70.7 
to 71.1)
Mean (SD)
ESG 75.9 (10.4), OSR 
68.2 (10.2)
Median (IQR)





Proportion male ESG 232 (65.5%), 
OSR 137 (51.9%)
% (95% CI):
1. ESG 58.7 (56.7 to 
60.7), OSR 55.4 (54.8 
to 56.3)
2. ESG 64.0 (59.9 to 








Outcomes           






Death from any cause Death from any cause
Complications
Death from any cause
Complications
Death from any 
cause
Complications
Long term Time to death 
from any cause





Time to death from any 
cause
Time to death from 
any cause





Time to major 
adverse event
Not reported Time to death from 
any cause
*1. Unmatched cohort, 2. Propensity matched cohort.
ESG, endovascular stent grafting; OSR, open surgical repair.
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All-cause mortality (following hospital discharge or after 30 
days)
Meta- analysis of the longer- term all- cause mortality was 
not possible as follow- up varied between the four studies 
that reported this outcome (Gore Tag,19–24 Goodney et 
al,25 Piffaretti et al26 and von Allmen et al.27 The results 
in the larger studies (Goodney et al,25 von Allmen et al27 
differed from those in the smaller studies (Gore Tag19–24 
and Piffaretti et al.26 We note that the analyses included 
the short- term deaths as well as those occurring beyond 
hospital discharge or after 30 days.
von Allmen et al27 reported time to death from any 
cause up to 5 years, throughout which OSR had higher 
overall survival. Adjusting for age and sex, ESG had 
higher odds of death at 1 year (OR 1.10; 95% CI 0.70 to 
1.73); p=0.667). Additionally, the HR for ESG relative to 
OSR up to 5 years, adjusting for age and sex, was HR=1.45 
(95% CI 1.08 to 1.94), p=0.013).
Goodney et al25 also reported time to death from any 
cause up to 5 years. Adjusting for age, sex, race, era of 
procedure and Charlson Comorbidity Score, 5- year 
survival for OSR in the unmatched cohort was higher 
than for ESG (89% vs 79%, log- rank p<0.0001). In the 
propensity- matched cohort, 5 years life- table analysis 
reported higher survival in the OSR group (81%–95% CI 
77% to 85%)) than for the ESG group (73%–95% CI 68% 
to 76%)) (log- rank p=0.007).
In the Gore TAG study,19–24 time to death from any 
cause over 5 years did not differ between the ESG and OSR 
groups, with survival probability at 5 years in both groups of 
63% (log rank p=0.625). Piffaretti et al 26 reported survival 
overall in the ESG group up to 5 years and the OSR group 
up to 13 years. For the 5 years in which survival is reported 
in both groups, ESG had a higher survival compared with 
OSR although this was based on only four deaths, and the 
follow- up periods differed substantially (log rank p>0.05).
Aneurysm/aortic-related mortality
Meta- analysis of aneurysm/aortic- related mortality could 
not be conducted. No studies reported aneurysm- related 
mortality during hospitalisation or up to 30 days sepa-
rately to the long- term. Von Allmen et al 201427 defined 
aortic- related mortality as any aortic- related death occur-
ring within 5 years of the index operation according to the 
International Classification of Diseases (ICD-10) codes 
referring to aorta, or cause of deaths closely related to 
complications of surgery (eg, paraplegia). Time to aortic- 
related death did not differ between OSR group than 
the ESG group during the 5 years follow- up (log- rank 
p=0.270). This study27 also reported adjusted (for age and 
sex) 5 years HR of 1.27 (95 CI 0.81 to 1.98; p=0.298) for 
ESG patients relative to OSR patients.
Gore TAG19–24 defined aneurysm- related mortality 
as deaths that occurred in hospital or within 30 days of 
initial procedure or any reintervention or a death due to 
the aneurysm or the treatment device and reported up to 
5 years, with longer time to aneurysm- related death in the 
ESG group over this period (log- rank p=0.012).
Short-term reinterventions
One study reported aortic- related re- interventions in 
21 (5.9%) ESG patients and 4 (1.5%) OSR patients, an 
adjusted OR of 2.97 (95%CI 1.09 to 8.10), p=0.033) for 
ESG versus OSR (von Allmen et al).27
Long-term reinterventions
Two studies reported this outcome (von Allmen et al27 and 
Gore TAG.19–24 von Allmen et al27 reported time to aortic- 
related reinterventions up to 5 years. Time to reinterven-
tion was longer in the OSR group compared with the ESG 
group (log- rank p=0.007), with adjusted (for age and sex) 
HR at 5 years of 1⋅70 (95% CI 1.11 to 2.60), p=0⋅014). In 
Gore TAG,19–24 time to reintervention over 5 years was 
longer in the ESG group (log- rank p=0.011). We note that 
these analyses included short- term reinterventions.
Complications
Table 2 summarises the short- term complications 
reported in all five studies.19 25–28 Most studies reported 
a small number of neurological, pulmonary, cardiac and 
Figure 2 Forest plot of unadjusted short- term all- cause 
mortality. ESG, endovascular stent grafting; OSR, open 
surgical repair.
Figure 3 Forest plot of unadjusted short- term all- cause 
mortality. sensitivity analysis. ESG, endovascular stent 
grafting; OSR, open surgical repair
Figure 4 Forest plot of adjusted short- term all- cause 
mortality. ESG, endovascular stent grafting; OSR, open 
surgical repair.
 on M









pen: first published as 10.1136/bm





7McCarthy A, et al. BMJ Open 2021;11:e043323. doi:10.1136/bmjopen-2020-043323
Open access
other complications. However, one larger study (Hughes 
et al)28 reported lower odds for ESG patients for neuro-
logical complications, OR of 0.48 (95% CI 0.26 to 0.86), 
p=0.015), pulmonary complications, OR: 0.38 (95%CI 
0.21 to 0.67), p=0.001) and cardiac complications, OR: 
0.24 (95% CI 0.15 to 0.37), p<0.001). The Gore TAG 
study19–24 reported endoleak rates for ESG patients of 
8.5%.
DISCUSSION
This is the first systematic review that reports results 
from non- randomised comparative studies regarding the 
effectiveness of elective ESG and OSR for arch and or 
descending TAA. Previous reviews have either included 
single- arm studies only30 or were comparative reviews that 
included non- elective procedures,9 31 or mixed patholo-
gies such as dissections.10 32 The results of these reviews 
may not be applicable to patients undergoing elective 
procedures for descending or arch TAA pathology.
In this review, only five comparative cohort studies were 
identified. The lack of RCTs comparing ESG and OSR 
for elective arch/DTA aneurysms may reflect the lack of 
equipoise from practitioners and patients. Well- designed 
non- randomised trials can demonstrate a high degree 
of concordance with the results of well- designed RCTs, 
provided that all confounders are adequately accom-
modated in the design and/or analysis.33 However, the 
studies identified in this review had moderate to serious 
risk of bias, mainly due to potential for confounding.
Although, complications in the short- term also appear 
to favour ESG, evidence regarding short- term complica-
tions is either lacking or inconsistently reported. All five 
studies19 25–28 suggested that the less invasive nature of 
ESG confers lower short- term mortality and fewer short- 
term non- fatal complications than OSR. The two small 
unadjusted studies19–24 26 had a much larger effect than 
larger studies.25 27 28 These larger studies used more robust 
methods for addressing confounding; this may indicate 
the presence of publication bias where only those smaller 
studies with larger effect sizes have been published.
Longer- term results are difficult to interpret since most 
data were not presented in a way to separate early risk 
from longer term survival. The two smaller studies19–24 26 
reported continuing survival benefit for ESG patients in 
the long term but are limited by small numbers, different 
recruitment periods, and failure to exclude early risk. 
The survival advantage associated with ESG in the Gore 
TAG19–24 study disappears by year 5, which suggests that 
the hazards are lower for OSR patients that survive the 
initial procedure. Conversely, the two larger studies (von 
Table 2 Short- term complications
Study Gore TAG Piffaretti et al26 Hughes et al28
Arm (participants) ESG (n=140) OSR (n=94) ESG (n=17) OSR (n=11) ESG (n=712) OSR (n=8255)
Neurological     
Paraplegia NR NR NR NR NR NR
Paraplegia/paraperisis 4 (3%) 13 (14%) NR NR NR NR
Cerebral vascular accident 5 (4%) 5 (4%) 2 (9%) 1 (12%) NR NR
Neurological- unspecified type NR NR NR NR 20 (2.8%) 273 (3.3%)
Respiratory     
Respiratory failure 5 (4%) 19 (20%) NR NR NR NR
Pneumonia NR NR 2 (12%) 3 (27%) NR NR
Pulmonary- unspecified type NR NR NR NR 17 (2.4%) 462 (5.6%)
Cardiac     
Myocardial Infarction 0 (0%) 1 (1%) 0 (0%) 1 (9%) NR NR
Cardiac- unspecified type NR NR NR NR 28 (2.9%) 1252 (15.2%)
Endoleaks     
Endoleaks 12 (8.5%) NR NR NR NR NR
Other     
Peripheral vascular disease 20 (14%) 4 (4%) NR NR NR NR
Renal failure 2 (1%) 12 (13%) NR NR NR NR
Wound infection/dehiscence 5 (4%) 10 (11%) NR NR NR NR
Gastrointestinal complication 3 (2%) 6 (6%) NR NR NR NR
Postimplant syndrome NR NR 4 (18%) 0 (0%) NR NR
Goodney et al25 and von Allmen et al27 did not report short- term complications.
ESG, endovascular stent grafting; NR, not reported; OSR, open surgical repair.
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Allmen et al27 and Goodney et al25 report that the short- 
term survival advantage of ESG were reversed by twelve 
months, and that the OSR group had an increasing 
survival advantage thereafter. Similarly, time to reinter-
vention favoured ESG in the smaller Gore TAG19–24 study, 
while time to aortic- related reinterventions favoured OSR 
in the larger study von Allmen et al.27
The evidence regarding mortality is inconsistent across 
the studies with more recent, larger studies25 27 28 reporting 
a more modest survival benefit for ESG in the short term 
and a survival benefit for OSR in the long- term. The two 
smaller studies19–24 26suggest a large reduction in the risk 
of mortality and short term complications in the short 
run and a survival benefit in the long- run for ESG.
Inconsistency of results across studies may be due 
to heterogeneity of the study populations, both within 
and across studies. Differences in recruitment periods 
may reflect changes in technology and practice in both 
groups. The larger studies25 27 28 were based on patients 
recruited up to twenty years later than the smaller 
studies. Outcomes may have improved differentially with 
OSR patients receiving proportionally better outcomes 
due to general improvements in surgical practice and 
patient selection over time.34 A potential reason for the 
reported long- term survival benefit of OSR in more 
recent, larger studies may be differences in patient risk in 
each intervention group. OSR is advocated for younger, 
lower- risk patients and ESG is preferred for older, higher- 
risk patients.35 This selection bias may not have been 
adequately accommodated in adjusted analyses.
The three large studies25 27 28 were based on admin-
istrative health records with case ascertainment that 
depends on accurate coding, which can vary across and 
within providers.36 Furthermore, one of the small studies, 
Piffaretti et al,26 recruited patients from one centre which 
may have compromised external validity as they may, for 
example, depend on the expertise within a centre and 
the nature of the patients that centre treats.37 38 Addi-
tionally, the Gore TAG study19–24 used a more restricted 
inclusion criteria for ESG patients compared with those 
who received OSR, potentially introducing heterogeneity 
between the two groups.
The headline conclusion of this review is that while 
there is a degree of variability, OSR is better for long- term 
survival and avoidance of reintervention, and that ESG 
is better for early outcomes. This conclusion is based on 
non- randomised comparisons in which the influence of 
important confounders for choice of intervention (ESG 
or OSR) has not been adjusted for. Deeper exploration is 
required, but randomised data may be difficult to acquire 
as there are well- established guidelines about which 
patients are favoured for OSR and which for ESG. Thus, 
to compare ESG and OSR it is first necessary to establish 
an understanding of the reasons driving clinical manage-
ment, for example, by a structured consensus analysis 
such as a Delphi study. Thereafter, unless there is clinical 
equipoise about which patients are best served by OSR 
or ESG, the best quality evidence to establish the relative 
merits of ESG and OSR for arch/DTA aneurysms is likely 
to be a systematic, prospective, observational, compara-
tive study, using individual patient data.
Limitations
The findings in this review are limited by the number and 
potential for confounding of the five studies19–28 identi-
fied, so that definitive conclusions are not possible. The 
adjustment for confounders is likely to be only partial 
and some bias in the estimates of differences in mortality 
and complications may persist, despite attempts to reduce 
bias in the larger studies identified. Statistical analysis of 
non- fatal complications was not possible due to limited 
and inconsistent reporting.
CONCLUSIONS
This systematic review is the first to consider evidence 
from non- randomised studies that directly compare ESG 
and OSR for the treatment of elective arch/DTA aneu-
rysms. Other reviews conducted in this area have been 
complicated by the inclusion of treatments for emergency 
cases or other thoracic aortic pathologies (eg, thoracic 
aortic ulcer, or dissection).
There is limited and increasingly dated evidence 
addressing the comparison of ESG and OSR in the 
management of elective arch and or DTA aneurysms. 
Further, high quality, evidence is required. Although large 
RCTs may not be possible in this relatively rare condition, 
future studies should use strong methodological study 
design in order to control for potential confounders and 
reduce potential biases. Additionally, given the current 
conflicting evidence, it is important that comparisons of 
OSR and ESG are conducted in both the short term and 
the long term.
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